CDNA
Caredx, Inc. Health Care Services-Medical Laboratories Russell 3000
$87.41Close
$4.5BMarket cap
$14.47 – $87.4152-week range
Late-januaryNext report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 99 · stronger than 99% of stocks over 12 months
- RS line at a 1-year high outperforming the S&P 500 more than at any point this year
- Near its high at its 52-week high
- Accumulation up-day volume 1.9× down-day volume over 50 sessions
- Earnings growing EPS +1026% year on year
Cautions
- Extended 8.2 ATR above its 50-day average
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
0%
1wk
up 26.3%
price change
1mo
up 34.5%
price change
12-month return
up 504%
market up 11% ·
its own up 501%
F-score
—
— Not assessed
Altman Z″
0.16
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
14.7×
price / book
Earnings yield
down 0.7%
EBIT / enterprise value
Cheaper than
20%
of the market · expensive
Revenue growth
up 14%
year on year
EPS growth
up 1026%
latest quarter
Sales growth
up 39%
latest quarter · -13 pts
ROE
down 6%
return on equity
Free cash margin
up 11%
$42.0M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.6%
$4.90 a day · 2×ATR $77.60
RS
99 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
2.7×
vs 50-day average
Up/down volume
1.85
50 sessions
Implied move
—
no scheduled report
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
Last reported
Oct 29, 2026
Results reaction
Oct 29, 2026+23% vs market2 sessions after results
Financials
- Net -6%
- Free cash 11%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $192.2M | $296.4M | $321.8M | $280.3M | $333.8M | $379.8M |
| Operating income | -$22.5M | -$29.7M | -$77.2M | -$203.4M | $40.8M | -$30.8M |
| Net income | -$18.7M | -$30.7M | -$76.6M | -$190.3M | $52.5M | -$21.4M |
| Net margin | -10% | -10% | -24% | -68% | 16% | -6% |
| Earnings per share | -$0.40 | -$0.59 | -$1.44 | -$3.54 | $0.93 | -$0.40 |
| Free cash flow | $33.4M | -$19.3M | -$25.2M | -$18.4M | $38.0M | $42.0M |
| Free cash margin | 17% | -7% | -8% | -7% | 11% | 11% |
| Cash | $134.7M | $348.5M | $89.9M | $82.2M | $114.7M | $65.4M |
| Long-term debt | $0 | — | — | — | — | — |
| Shareholders' equity | $277.7M | $465.9M | $430.9M | $261.3M | $378.4M | $303.1M |
| Shares outstanding | 49.44m | 52.92m | 53.53m | 51.50m | 54.77m | 50.92m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 29, 2026 | Quarterly ↗ | Sep 30, 2026 | 29d |
| Jul 30, 2026 | Quarterly ↗ | Jun 30, 2026 | 30d |
| Apr 28, 2026 | Quarterly ↗ | Mar 31, 2026 | 28d |
| Feb 25, 2026 | Annual ↗ | Dec 31, 2025 | 56d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| Apr 30, 2025 | Quarterly ↗ | Mar 31, 2025 | 30d |
| Feb 28, 2025 | Annual ↗ | Dec 31, 2024 | 59d |
| Nov 4, 2024 | Quarterly ↗ | Sep 30, 2024 | 35d |
| Jul 31, 2024 | Quarterly ↗ | Jun 30, 2024 | 31d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results · Regulation FD ↗ |
| Jul 30, 2026 | Results · Regulation FD ↗ |
| Jul 7, 2026 | Acquisition or disposal · Regulation FD ↗ |
| Jun 15, 2026 | Director or officer change · Shareholder vote ↗ |
| Apr 28, 2026 | Material agreement · Results · Regulation FD · Other events ↗ |
| Apr 16, 2026 | Material agreement · Results · Regulation FD ↗ |
| Feb 24, 2026 | Results ↗ |
| Jan 12, 2026 | Results ↗ |
| Dec 18, 2025 | Other events ↗ |
| Dec 15, 2025 | Charter or bylaws ↗ |
| Nov 4, 2025 | Results · Regulation FD ↗ |
| Oct 24, 2025 | Director or officer change ↗ |